Additionally, the phase II BYLieve study provided evidence that HR‐positive/HER2‐negative advanced breast cancer patients with PIK3CA mutations, who had previously been treated with CDK4/6i, benefited from alpelisib in combination with either aromatase inhibitors (AI) or fulvestrant [48]. Here, CDK4 is linked to breast carcinoma.